OGN at a glance
Organon & Co (OGN, SEC CIK 1821825) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Organon & Co (OGN) reported revenue of $6.2 billion (down 2.9% from FY2024) and net income of $187.0 million. Diluted EPS was $0.72.
- As of September 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Organon & Co (OGN) shares worth $1.4 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.2B
- −2.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 37 funds
- $1.4B · +0 vs prior quarter
- Latest 8-K
- Oct 30, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $1.574B, down 2% YoY, including approximately $12M favorable foreign exchange impact
- Quarterly gross margin 61.2% vs 59.6% YoY, based on gross profit of $965M and revenue of $1.574B
- Best product: Hadlima sales up 35% YoY; worst: Ontruzant sales down 77%
- Cash $1.46B; nine-month operating cash flow $702M vs $559M YoY
- Headwinds: supply constraints, Nexplanon demand weakness, VBP expected to continue affecting general medicines for several quarters
Risk Factors
- Newly added patent risk: four Vtama generic ANDAs filed, targeting twelve or nine Orange Book patents expiring 2036–2039
- Regulatory risk: SEC investigation into Nexplanon wholesaler sales, following Organon’s October 26, 2025 voluntary disclosure
- Legal risk: third stockholder derivative suit filed September 19, 2026, adding allegations concerning capital allocation, debt reduction and Nexplanon
- Operational risk: Samsung returned Ontruzant and Aybintio commercialization rights in specified ex-U.S. markets, with transitions through 2029
- Financial risk: $8,554 million debt principal, including $3,483 million due in 2028 and average maturity of 3.8 years
AI summary of the OGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 2026 adjusted net income $256M, down from $263M; adjusted diluted EPS $0.94 versus $1.01
- Nine-month adjusted net income $674M, down from $789M; adjusted diluted EPS $2.51 versus $3.03
Item 7.01: Regulation FD Disclosure
- Q3 2026 results covered quarter ended September 30, 2026, with GAAP disclosures in the Form 10-Q
- Supplemental non-GAAP metrics furnished in Exhibit 99.1 for investor analysis alongside GAAP results
Item 7.01: Regulation FD Disclosure
- Q2 2026 results covered quarter ended June 30, 2026, with GAAP financials in Form 10-Q filed July 31, 2026
- Quarterly earnings release and conference call suspended due to pending merger with Sun Pharmaceutical Industries
Item EX-99.1: Item EX-99.1
- Q2 2026 adjusted net income $230M, down from $261M; adjusted diluted EPS $0.85 vs $1.00
- Six-month adjusted EPS $1.57 vs $2.02, signaling weaker underlying earnings despite GAAP net income rising to $254M
Item 5.07: Submission of Matters to a Vote of Security Holders
- Merger agreement with Sun Pharma approved, clearing the key shareholder vote for Organon’s acquisition
- 192,776,552 votes for versus 2,573,118 against, representing strong approval among votes cast
AI summaries of OGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OGN
Don't miss the next OGN filing
- Alerts as it files. A push when OGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OGN, by share count.
- Ask anything. An AI agent that reads every OGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Morrissey Joseph T. Jr. | M | Nov 13, 2026 | 43,744 | - |
| Drinane Juliana Papa | M | Nov 13, 2026 | 21,872 | - |
| Drinane Juliana Papa | M | Nov 13, 2026 | 21,872 | - |
| Morrissey Joseph T. Jr. | F | Nov 13, 2026 | 13,551 | $13.90 |
| Morrissey Joseph T. Jr. | M | Nov 13, 2026 | 43,744 | - |
| Drinane Juliana Papa | F | Nov 13, 2026 | 7,492 | $13.90 |
| Holzbaur Lynette | F | Nov 7, 2026 | 689 | $13.87 |
| Holzbaur Lynette | M | Nov 7, 2026 | 2,418 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $6.3B | $6.4B | $6.2B |
| Gross Profit | $3.7B | $3.7B | $3.3B |
| Net Income | $1.0B | $864.0M | $187.0M |
| Gross Margin | 59.8% | 58.0% | 53.3% |
| Net Margin | 16.3% | 13.5% | 3.0% |
| Balance Sheet | |||
| Total Assets | - | $13.1B | $12.9B |
| Equity | - | $472.0M | $752.0M |
| ROE | - | 183.1% | 24.9% |
| Per Share | |||
| EPS | $3.99 | $3.33 | $0.72 |
| Cash Flow | |||
| Operating CF | - | $939.0M | $700.0M |
| CapEx | - | $175.0M | $162.0M |
Source: XBRL data in Organon & Co (OGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 37 | $1.36B |
| Q2 2026 | 37 | $1.33B |
| Q1 2026 | 39 | $699.0M |
| Q4 2025 | 34 | $837.3M |
| Q3 2025 | 35 | $1.17B |
| Q2 2025 | 36 | $1.15B |
| Q1 2025 | 31 | $1.06B |
| Q4 2024 | 29 | $876.0M |
- Millennium Management+1.69M (+49%)
- Morgan Stanley+736.7K (+33%)
- Bank of America Corp+412.6K (+64%)
- Vanguard Portfolio Management LLC+221.2K (+1%)
- State Street Corp+99.9K (+1%)
- Goldman Sachs Group−2.32M (-45%)
- AQR Capital Management−543.4K (-44%)
- Citadel Advisors LLC−219.2K (-64%)
- Citigroup−199.8K (-51%)
- BlackRock−135.0K (-0%)
- Soros Fund Management+2.95M
- FMR LLC (Fidelity)−1.19M
Source: 13F-HR filings on SEC EDGAR (aggregated from 278 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 10-Q | Oct 30, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | - | - |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OGN SEC filings: frequently asked questions
Which institutions hold OGN stock?
As of September 30, 2026, the largest Organon & Co (OGN) holders among the 13F filers tracked by SignalX were BlackRock ($437.3 million), Vanguard Portfolio Management LLC ($210.3 million), Vanguard Capital Management LLC ($163.3 million), State Street Corp ($133.7 million), Millennium Management ($70.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Organon & Co (OGN) reported revenue of $6.2 billion (down 2.9% from FY2024) and net income of $187.0 million. Diluted EPS was $0.72. The figures come from the XBRL data in the 10-K.
What did OGN report in its latest 8-K?
Organon & Co (OGN) filed an 8-K on October 30, 2026 reporting Item 7.01 (Regulation FD Disclosure). Q3 2026 adjusted net income $256M, down from $263M; adjusted diluted EPS $0.94 versus $1.01.
What are the latest OGN SEC filings?
Organon & Co (OGN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 16, 2026.
What is OGN's SEC CIK number?
Organon & Co (OGN)'s SEC Central Index Key (CIK) is 1821825. EDGAR lists every OGN filing under that number.
Ask anything about OGN
The research agent reads OGN's filings, financials, insider trades and 13F holders, then answers with sources.